Zacks Research Has Bearish Estimate for PBH Q2 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research lowered their Q2 2027 earnings per share estimates for Prestige Consumer Healthcare in a research note issued on Tuesday, June 2nd. Zacks Research analyst Team now expects that the company will post earnings per share of $1.06 for the quarter, down from their prior estimate of $1.14. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.45 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2027 earnings at $1.19 EPS, FY2027 earnings at $4.44 EPS, Q2 2028 earnings at $1.11 EPS, Q3 2028 earnings at $1.23 EPS, Q4 2028 earnings at $1.41 EPS, FY2028 earnings at $4.72 EPS and FY2029 earnings at $5.10 EPS.

A number of other equities analysts also recently commented on PBH. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Down 0.1%

NYSE:PBH opened at $45.91 on Wednesday. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of 11.74, a price-to-earnings-growth ratio of 1.48 and a beta of 0.35. Prestige Consumer Healthcare has a one year low of $42.62 and a one year high of $87.12. The stock has a 50-day simple moving average of $54.34 and a 200 day simple moving average of $60.36. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same quarter last year, the business posted $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA raised its holdings in shares of Prestige Consumer Healthcare by 10.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after buying an additional 60,496 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Prestige Consumer Healthcare by 547.4% during the fourth quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after buying an additional 520,186 shares during the last quarter. Leeward Investments LLC MA raised its holdings in shares of Prestige Consumer Healthcare by 23.3% during the fourth quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock valued at $23,894,000 after buying an additional 73,162 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Prestige Consumer Healthcare by 30.1% during the third quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock valued at $28,656,000 after buying an additional 106,224 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Prestige Consumer Healthcare by 1.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock valued at $98,776,000 after buying an additional 21,085 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Zacks Research nudged its Q4 2028 EPS estimate higher to $1.41 from $1.36, suggesting slightly better longer-term profit expectations. MarketBeat PBH article
• Neutral Sentiment: Zacks Research also raised its FY2029 EPS forecast to $5.10, indicating expectations for earnings growth farther out. MarketBeat PBH article
• Negative Sentiment: The analyst lowered several near- to medium-term estimates, including FY2027 EPS to $4.44 from $4.76, FY2028 EPS to $4.72 from $5.05, Q2 2027 EPS to $1.06 from $1.14, Q3 2027 EPS to $1.19 from $1.21, Q2 2028 EPS to $1.11 from $1.24, and Q3 2028 EPS to $1.23 from $1.26. MarketBeat PBH article
• Negative Sentiment: PBH is also facing investor-overhang risk after Pomerantz LLP announced an investigation on behalf of shareholders, which can add uncertainty and weigh on sentiment. GlobeNewswire investor alert

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).